截止目前,引用Bioss產(chǎn)品發(fā)表的文獻共22023篇,總影響因子100843.61分,發(fā)表在Nature, Science, Cell以及Immunity等頂級期刊的文獻共54篇,合作單位覆蓋了清華、北大、復(fù)旦、華盛頓大學(xué)、麻省理工學(xué)院、東京大學(xué)以及紐約大學(xué)等國際研究機構(gòu)上百所。
我們每月收集引用Bioss產(chǎn)品發(fā)表的文獻。若您在當(dāng)月已發(fā)表SCI文章,但未被我公司收集,請致電Bioss,我們將贈予現(xiàn)金鼓勵,金額標(biāo)準(zhǔn)請參考“發(fā)文章 領(lǐng)獎金"活動頁面。
近期收錄2022年10月引用Bioss產(chǎn)品發(fā)表的文獻共207篇(圖一,綠色柱),文章影響因子(IF) 總和高達1372.784,其中,10分以上文獻22篇(圖二)。
圖一
圖二
本文主要分享引用Bioss產(chǎn)品發(fā)表文章至Nature Nanotechnology, Immunity, Cancer Cell等期刊的7篇 IF>15 的文獻摘要,讓我們一起欣賞吧。
Molecular Cancer
[IF=41.444]
作者單位:德國馬爾堡菲利普斯大學(xué)德國肺研究中心,吉森大學(xué)和馬爾堡肺中心分子腫瘤研究所
In vivo gene editing of somatic cells with CRISPR nucleases has facilitated the generation of autochthonous mouse tumors, which are initiated by genetic alterations relevant to the human disease and progress along a natural timeline as in patients. However, the long and variable, orthotopic tumor growth in inner organs requires sophisticated, time-consuming and resource-intensive imaging for longitudinal disease monitoring and impedes the use of autochthonous tumor models for preclinical studies.
Methods
To facilitate a more widespread use, we have generated a reporter mouse that expresses a Cre-inducible luciferase from Gaussia princeps (GLuc), which is secreted by cells in an energy-consuming process and can be measured quantitatively in the blood as a marker for the viable tumor load...
Cell Metabolism
[IF=31.373]
Anti-ox-LDL pAb; IF
摘要:The underlying cellular events driving kidney fibrogenesis and metabolic dysfunction are incompletely understood. Here, we employed single-cell combinatorial indexing RNA sequencing to analyze 24 mouse kidneys from two fibrosis models. We profiled 309,666 cells in one experiment, representing 50 cell types/states encompassing epithelial, endothelial, immune, and stromal populations. Single-cell analysis identified diverse injury states of the proximal tubule, including two distinct early-phase populations with dysregulated lipid and amino acid metabolism, respectively. Lipid metabolism was defective in the chronic phase but was transiently activated in the very early stages of ischemia-induced injury, where we discovered increased lipid deposition and increased fatty acid β-oxidation. Perilipin 2 was identified as a surface marker of intracellular lipid droplets, and its knockdown in vitro disrupted cell energy state maintenance during lipid accumulation. Surveying epithelial cells across nephron segments identified shared and unique injury responses. Stromal cells exhibited high heterogeneity and contributed to fibrogenesis by epithelial-stromal crosstalk.
JOURNAL OF CLINICAL
INVESTIGATION [IF=19.456]
Anti-C5b-9 pAb; IHC
MOLECULAR CELL
[IF=19.328]
文獻引用抗體:bs-8170R
Anti-KMT3B pAb; IF
作者單位:美國哥倫比亞大學(xué)歐文醫(yī)學(xué)中心遺傳與發(fā)育系
Nature Communications
[IF=17.694]
文獻引用抗體:bs-11040R
作者單位:美國賓夕法尼亞州匹茲堡市匹茲堡大學(xué)醫(yī)學(xué)院眼科學(xué)系
摘要:The retinal pigment epithelium (RPE) plays an important role in the development of diabetic retinopathy (DR), a leading cause of blindness worldwide. Here we set out to explore the role of Akt2 signaling—integral to both RPE homeostasis and glucose metabolism—to DR. Using human tissue and genetically manipulated mice (including RPE-specific conditional knockout (cKO) and knock-in (KI) mice), we investigate whether Akts in the RPE influences DR in models of diabetic eye disease. We found that Akt1 and Akt2 activities were reciprocally regulated in the RPE of DR donor tissue and diabetic mice. Akt2 cKO attenuated diabetes-induced retinal abnormalities through a compensatory upregulation of phospho-Akt1 leading to an inhibition of vascular injury, inflammatory cytokine release, and infiltration of immune cells mediated by the GSK3β/NF-κB signaling pathway; overexpression of Akt2 has no effect. We propose that targeting Akt1 activity in the RPE may be a novel therapy for treating DR.
Nature Communications
[IF=17.694]
文獻引用抗體:
bs-3420R
Anti-Phospho-Smad2 (Ser245 + Ser250 + Ser255) pAb;FCM
bs-3425R
Anti-Phospho-Smad3 (Ser423 + Ser425) pAb;FCM
作者單位:首爾國立大學(xué)醫(yī)學(xué)院生物醫(yī)學(xué)科學(xué)系解剖與細(xì)胞生物學(xué)
摘要:Pancreatic ductal adenocarcinoma (PDAC) has a poor 5-year overall survival rate. Patients with PDAC display limited benefits after undergoing chemotherapy or immunotherapy modalities. Herein, we reveal that chemotherapy upregulates placental growth factor (PlGF), which directly activates cancer-associated fibroblasts (CAFs) to induce fibrosis-associated collagen deposition in PDAC. Patients with poor prognosis have high PIGF/VEGF expression and an increased number of PIGF/VEGF receptor-expressing CAFs, associated with enhanced collagen deposition. We also develop a multi-paratopic VEGF decoy receptor (Ate-Grab) by fusing the single-chain Fv of atezolizumab (anti-PD-L1) to VEGF-Grab to target PD-L1-expressing CAFs. Ate-Grab exerts anti-tumor and anti-fibrotic effects in PDAC models via the PD-L1-directed PlGF/VEGF blockade. Furthermore, Ate-Grab synergizes with gemcitabine by relieving desmoplasia. Single-cell RNA sequencing identifies that a CD141+ CAF population is reduced upon Ate-Grab and gemcitabine combination treatment. Overall, our results elucidate the mechanism underlying chemotherapy-induced fibrosis in PDAC and highlight a combinatorial therapeutic strategy for desmoplastic cancers.
Nature Communications
[IF=17.694]
文獻引用抗體:bs-4682R